Merck KGaA Reports on Market Environment and Strategic Partnerships

Merck KGaA, a global pharmaceutical and chemicals company, has been operating in a challenging market environment. The company’s stock price has been under pressure since autumn 2024, despite analysts’ forecasts.

• The stock price has been impacted by market fluctuations.
• Analysts’ forecasts have been optimistic, but the market has not reflected this optimism.

However, the stock has recently reached a crucial support zone, suggesting that the downward trend may be reversing.

• The stock price has reached a support zone.
• The downward trend may be reversing.

Merck has announced a significant partnership with Neoclease, a biotech startup that has developed a gene-editing platform to treat Parkinson’s disease. This collaboration is part of Merck’s Advance Biotech Grant program, which has supported over 40 startups globally since its inception in 2014.

• Merck has partnered with Neoclease.
• The partnership is part of the Advance Biotech Grant program.
• The grant program has supported over 40 startups globally since its inception in 2014.

The company’s focus on innovative therapies and partnerships is expected to drive growth in the oligonucleotide synthesis market, which is projected to reach USD 5.75 billion by 2031.

• The oligonucleotide synthesis market is projected to reach USD 5.75 billion by 2031.
• Merck’s focus on innovative therapies and partnerships is expected to drive growth in this market.